Bank of New York Mellon Corp - IMMUNOVANT INC ownership

IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 97 filers reported holding IMMUNOVANT INC in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of IMMUNOVANT INC
ValueSharesWeighting
Q3 2023$7,379,096
+113.1%
192,214
+5.3%
0.00%
+100.0%
Q2 2023$3,463,278
+32.1%
182,566
+8.0%
0.00%0.0%
Q1 2023$2,622,338
-11.8%
169,074
+0.9%
0.00%0.0%
Q4 2022$2,973,303
+256.1%
167,510
+11.9%
0.00%
Q3 2022$835,000
+51.3%
149,674
+5.8%
0.00%
Q2 2022$552,000
-31.8%
141,433
-3.7%
0.00%
Q1 2022$809,000
-34.9%
146,799
+0.6%
0.00%
Q4 2021$1,243,000
+1.8%
145,866
+3.8%
0.00%
Q3 2021$1,221,000
-6.0%
140,473
+14.3%
0.00%
Q2 2021$1,299,000
-45.6%
122,868
-17.5%
0.00%
Q1 2021$2,389,000
-69.0%
148,950
-10.9%
0.00%
-100.0%
Q4 2020$7,718,000
+42.0%
167,111
+8.2%
0.00%
+100.0%
Q3 2020$5,434,000
+197.1%
154,446
+105.6%
0.00%
Q2 2020$1,829,00075,1040.00%
Other shareholders
IMMUNOVANT INC shareholders Q2 2022
NameSharesValueWeighting ↓
Alpine Global Management, LLC 4,448,017$17,347,0004.39%
Deep Track Capital, LP 9,455,000$36,875,0002.42%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 233$60,000,0000.63%
Octagon Capital Advisors LP 579,061$2,258,0000.60%
Eventide Asset Management 5,372,512$20,953,0000.45%
WITTENBERG INVESTMENT MANAGEMENT, INC. 174,000$679,0000.29%
Frazier Life Sciences Management, L.P. 585,759$2,284,0000.22%
BCK CAPITAL MANAGEMENT LP 54,293$212,0000.16%
PLATINUM INVESTMENT MANAGEMENT LTD 777,590$3,033,0000.12%
Bridgefront Capital, LLC 15,649$61,0000.07%
View complete list of IMMUNOVANT INC shareholders